Clonal analysis of human recurrent superficial bladder cancer by immunohistochemistry of p53 and retinoblastoma proteins

被引:23
|
作者
Chern, HD
Becich, MJ
Persad, RA
Romkes, M
Smith, P
Collins, C
Li, YH
Branch, RA
机构
[1] UNIV PITTSBURGH,CTR CLIN PHARMACOL ENVIRONM & OCCUPAT HLTH,PITTSBURGH,PA 15261
[2] UNIV PITTSBURGH,DEPT PATHOL,PITTSBURGH,PA 15261
[3] UNIV PITTSBURGH,DEPT BIOSTAT,PITTSBURGH,PA 15261
[4] UNIV BRISTOL,DEPT PATHOL,BRISTOL,AVON,ENGLAND
[5] UNIV BRISTOL,DEPT UROL,BRISTOL,AVON,ENGLAND
来源
JOURNAL OF UROLOGY | 1996年 / 156卷 / 05期
关键词
bladder neoplasms; genes; p53; retinoblastoma;
D O I
10.1016/S0022-5347(01)65550-2
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: To investigate the clonal origin of malignant cells in recurrent superficial bladder cancer. Materials and Methods: We compared the protein expression of p53 and retinoblastoma (Rb) by immunohistochemistry using antibody P1801 and PMG3-245, respectively, in 13 patients at the time of primary superficial bladder cancer resection (6 Ta and 7 Tl) and their 15 corresponding recurrences of disease, Mutations in p53 and Rb is ere inferred on the basis of immunoperoxidase staining. Results: At the time of initial tumor resection, a p53 mutation was observed in 5 patients (39%) and an Rb mutation was observed in 3 (23%). The p53/Rb mutation status of recurrent bladder cancers completely matched their corresponding primary bladder cancer. Conclusions: The chance that recurrent bladder cancer originated from independent clones in this study was extremely small (p < 10(-6)). This result strongly supports the monoclonal origin of recurrent superficial bladder cancer.
引用
收藏
页码:1846 / 1849
页数:4
相关论文
共 50 条
  • [21] P53 mutations in human urinary bladder cancer.
    Berggren, P
    Steineck, G
    Adolfsson, J
    Borgström, E
    Hansson, J
    Norming, U
    Sandstedt, B
    Wijkström, H
    Hemminki, K
    BRITISH JOURNAL OF CANCER, 1999, 80 : 71 - 71
  • [22] P53 AND BLADDER-CANCER
    LI, WW
    LI, VW
    TSAKAYANNIS, D
    NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (14): : 957 - 957
  • [23] p53 and treatment of bladder cancer
    Scott W. Lowe
    Tyler Jacks
    Nature, 1997, 385 : 124 - 125
  • [24] p53 and chemosensitivity in bladder cancer
    Hiroyuki Nishiyama
    Jun Watanabe
    Osamu Ogawa
    International Journal of Clinical Oncology, 2008, 13 : 282 - 286
  • [25] Can p53 staining be used to identify patients with aggressive superficial bladder cancer?
    Masters, JRW
    Vani, UD
    Grigor, KM
    Griffiths, GO
    Crook, A
    Parmar, MKB
    Knowles, MA
    JOURNAL OF PATHOLOGY, 2003, 200 (01): : 74 - 81
  • [26] p53 and treatment of bladder cancer
    Richard J. Cote
    David Esrig
    Susan Groshen
    Peter A. Jones
    Donald G. Skinner
    Nature, 1997, 385 : 123 - 124
  • [27] p53 and chemosensitivity in bladder cancer
    Nishiyama, Hiroyuki
    Watanabe, Jun
    Ogawa, Osamu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2008, 13 (04) : 282 - 286
  • [28] Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer
    Tuna, B
    Yörükoglu, K
    Tüzel, E
    Güray, M
    Mungan, U
    Kirkali, Z
    PATHOLOGY RESEARCH AND PRACTICE, 2003, 199 (05) : 323 - 328
  • [29] P53 analysis in gallbladder cancer: Comparison of gene analysis versus immunohistochemistry
    Puhalla, H
    Kandioler, D
    Ludwig, C
    Filipits, M
    Wrba, F
    Laengle, F
    Jakesz, R
    Gruenberger, T
    ANTICANCER RESEARCH, 2004, 24 (2C) : 1201 - 1206
  • [30] Immunohistochemistry of p16 and p53 in vulvar cancer
    Florencia Falcon, Maria
    Eugenia Paradeda, Maria
    Garcia Kamermann, Florencia
    Maldonado, Veronica
    Diaz, Lili
    Cardinal, Lucia
    MEDICINA-BUENOS AIRES, 2020, 80 (02) : 127 - 133